Reveal CTC heterogeneity to guide cancer therapy
QCDx is a medical device company that designs, manufactures, and sells instruments, consumables and reagents for the detection of rare cells in the blood circulation.
Our mission is to reveal circulating tumor cell heterogeneity early in cancer onset and throughout the disease trajectory to deliver precision cancer diagnosis that will guide the clinical oncologist to optimize treatment, monitor therapy, characterize metastasis and assess treatment toxicity.
Ultimately, improve patient outcomes and their quality of life.
QCDx addresses unmet need to detect and isolate intact and live, the very rare Circulating Tumor Cells (CTCs) while analyzing all nucleated cells in a blood sample.
When biopsy is not an option, these cells can offer the real-time information on the disease biology at the time when the blood sample was collected.
They reveal molecular targets that the treating physician can use to optimize therapy.
In cancer research and the pharmaceutical industry they can enable development of novel therapeutics. Also, they may be useful for testing the effect of drugs before they are given to the patient.
The QCDx technology offers:
ENRICHMENT-FREE rare cell detection and deep characterization.
INTACT CELL visualization in a life-sustaining 3D suspension
LIVE CELL visualization over long periods of time
SINGLE CELL isolation - intact and live
3D-CULTURE of cells under continual visualization
The RareScope™ Rare Cell Detection
The RareScope analyzes cells from the patient’s blood, without the need of a microscopy slide.
Cells remain morphologically intact.
Selected cells will be isolated with the RarePicker™ micro-manipulator, intact or live for down-stream molecular analyses.
They are visualized via a 3D tomographic method after staining with fluorescent markers.
The RarePrep™ fixture holds more than 15 million cells immobilized in life-sustaining hydrogel.
The RareVivo™ specimen chamber is designed as a continuous 3D culture environment for the cell suspension. Flow-through media maintain cells viable and deliver bioactive substances to the immobilized cell population, while continually visualized. By observing effect of bioactive substances on target cells, the instrument can be used to evaluate their beneficial action and/or undesired toxicity.